Regulatory Updates News
🇺🇸 FDAFDA breaking news and regulatory updates for BD, investors, and analysts
Showing 1–12 of 113 articles
Eli Lilly Acquires 3 Vaccine Developers in $3.8B Deal
Eli Lilly has announced its acquisition of three vaccine developers for up to $3.8 billion, marking a pivotal moment in the ongoing M&A activity within the pharmaceutical sector. This move is expected to reshape market dynamics and investment strategies.
Lilly and Gilead Lead Pharma's M&A Boom: Market Analysis
Eli Lilly and Gilead Sciences are at the forefront of a significant M&A boom in the pharmaceutical sector, reshaping the market landscape. This article analyzes the implications for business development teams and investors.
Inventiva Strengthens Leadership Team Ahead of Lanifibranor Phase 3 Data
Inventiva has announced key leadership changes in anticipation of the upcoming Phase 3 data readout for Lanifibranor, which could significantly impact the market.
Top 10 Most Anticipated Drug Launches of 2026
This article highlights the most anticipated drug launches of 2026, detailing their potential impact on the pharmaceutical landscape. Learn about key players and clinical trials shaping the future of medicine.
AstraZeneca and Daiichi's New Drug Approved for Breast Cancer
AstraZeneca and Daiichi's drug has received FDA approval as a first-line treatment for triple-negative breast cancer, marking a significant advancement in oncology. This approval is poised to reshape treatment protocols and market dynamics.
3 Overlooked Stocks Set to Soar in 2026 — Clinical Trials
This article highlights three overlooked pharmaceutical stocks that are expected to rise significantly by 2026, driven by promising clinical trials. Investors and analysts should take note of these potential opportunities.
FDA Restricts Large-Scale Compounding of Weight Loss Drugs
On May 4, 2026, the FDA announced restrictions on large-scale compounding of three weight loss drugs, signaling significant changes in the pharmaceutical landscape. This move has implications for investors and pharmaceutical teams alike.
FDA Guidelines Enhance Generic Bioequivalence in Oncology Drugs
The FDA has released product-specific guidelines that enhance the evaluation of generic bioequivalence in key oncology drugs. This development has significant implications for pharmaceutical companies and investors.
5 FDA Drug Approvals to Watch in 2026
As we look ahead to 2026, several FDA drug approvals are poised to reshape the pharmaceutical industry. This article highlights five key approvals that investors and analysts should monitor closely.
NeuroSense's Regulatory Advancements in Alzheimer's Trials
NeuroSense is advancing its Alzheimer's clinical trials with a strengthened data package, aiming for key regulatory milestones. Investors should track these developments closely.
Lifesaving Upgrades: 40 Years of FDA Oncology Approvals
This article reviews four decades of FDA oncology approvals, highlighting key developments and their implications for the pharmaceutical industry.
FDA Declines Guidance on Foreign Drug Imports: Key Regulatory Update
The FDA has opted not to provide specific guidance on foreign drug imports, raising concerns among pharmaceutical stakeholders. This decision could significantly affect market strategies and regulatory compliance.